Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 4/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL23088726 | 1.00 | GSR (0.61) | GSRSLC7A5SLC1A2SLC1A3SLC1A1 | |
| Lysine SCHEMBL1537438 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL3358270 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL21816467 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL5084119 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL1537434 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL746846 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL746845 | 0.92 | GSR (0.71) | GSRTHRBARG2ARG1NOS2 | |
| Lysine SCHEMBL8860269 | 0.91 | GSR (0.50) | GSRSLC7A5SLC1A2SLC1A3SLC1A1 | |
| Lysine SCHEMBL8860263 | 0.91 | GSR (0.50) | GSRSLC7A5SLC1A2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317412-A1 | Induction of an immune response against streptococcus pneumoniae polyaccharides | ALEXANDER JEFFERY L | 2009-12-24 | — | — | US | claimed |
| EP-1781326-A4 | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES | PHARMEXA INC (US) | 2009-01-14 | — | — | EP | claimed |
| CN-1993141-A | Induction of immune response against Streptococcus pneumoniae polysaccharides | EPIMMUNE INC (US) | 2007-07-04 | — | — | CN | claimed |
| EP-1781326-A2 | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES | Pharmexa Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2005120563-A2 | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES | PHARMEXA INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050049197-A1 | Induction of immune response against desired determinants | EPIMMUNE INC. (US) | 2005-03-03 | — | — | US | claimed |
| EP-0876398-B1 | INDUCTION OF IMMUNE RESPONSE AGAINST DESIRED DETERMINANTS | EPIMMUNE INC (US) | 2002-07-17 | — | — | EP | claimed |
| US-6413935-B1 | OLIGOPEPTIDE | EPIMMUNE INC. | 2002-07-02 | — | — | US | claimed |
| US-5736142-A | GENETIC ENGINEERING | CYTEL CORPORATION (US) | 1998-04-07 | — | — | US | claimed |
| CN-1135181-A | Altering immune responses using pan-DR binding peptides | CYTEL CORP (US) | 1996-11-06 | — | — | CN | claimed |
| US-20090317412-A1 | Induction of an immune response against streptococcus pneumoniae polyaccharides | ALEXANDER JEFFERY L | 2009-12-24 | — | — | US | disclosed |
| EP-1781326-A4 | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES | PHARMEXA INC (US) | 2009-01-14 | — | — | EP | disclosed |
| CN-1993141-A | Induction of immune response against Streptococcus pneumoniae polysaccharides | EPIMMUNE INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1781326-A2 | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES | Pharmexa Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7202351-B1 | Alteration of immune response using pan DR-binding peptides | PHARMEXA INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0735893-A4 | ALTERATION OF IMMUNE RESPONSE USING PAN DR-BINDING PEPTIDES | CYTEL CORP (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997026784-A1 | INDUCTION OF IMMUNE RESPONSE AGAINST DESIRED DETERMINANTS | CYTEL CORPORATION (US) | 1997-07-31 | — | — | WO | disclosed |
| CN-1135181-A | Altering immune responses using pan-DR binding peptides | CYTEL CORP (US) | 1996-11-06 | — | — | CN | disclosed |
| EP-0735893-A1 | ALTERATION OF IMMUNE RESPONSE USING PAN DR-BINDING PEPTIDES | CYTEL CORPORATION (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995007707-A1 | ALTERATION OF IMMUNE RESPONSE USING PAN DR-BINDING PEPTIDES | CYTEL CORPORATION (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317412-A1 | Induction of an immune response against streptococcus pneumoniae polyaccharides | CD14, TLR3, HLA-DRB1 | GSR 2900/4885SLC7A5 2952/4885SLC1A2 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.